个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Tumor burden score and carcinoembryonic antigen predict outcomes in patients with intrahepatic cholangiocarcinoma following liver resection: a multi‑institutional analysis

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Fu Jun[1,2] * ; Zheng Lifang[1] * ; Tang Shicuan[1] * ; Lin Kongying[1] ; Zheng Shuguo[3] ; Bi Xinyu[4] ; Wang Jianming[5] ; Guo Wei[6] ; Li Fuyu[7] ; Wang Jian[8] ; Wang Kui[9] ; Li Haitao[1] ; Zeng Yongyi[1,2] ;
单位： [1]Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, 312 Xihong Road, Fuzhou, China [2]Department of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, China [3]Department of Hepatobiliary Surgery, The Southwest Hospital Affiliated to the Army Medical University, Chongqing, China [4]Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China [5]Department of Hepatobiliary Surgery,Tongji Hospital Affiliated to Tongji Medical College,Huazhong University of Science Technology,Wuhan,China [6]Department of Hepatobiliary Surgery, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China [7]Department of Hepatobiliary Surgery, The West China Hospital of Sichuan University, Chengdu, China [8]Department of Hepatobiliary Surgery, Renji Hospital, Shanghai Jiaotong University, Shanghai, China [9]Department of Hepatic Surgery (II), Eastern Hepatobiliary Surgery Hospital, Navy edical University, Shanghai, China
出处：
DOI： 10.1186/s12885-024-12091-2
ISSN：

关键词： Primary liver cancer Tumor burden score CEA Multi−institutional database Prediction model

摘要：
The prognostic significance of tumor burden score (TBS) in relation to carcinoembryonic antigen (CEA) has not been investigated among patients undergoing hepatectomy for intrahepatic cholangiocarcinoma (ICC). This study aimed to develop and validate a simplified model, a combination of TBS and CEA (CTC grade), for predicting the long-term outcomes of postoperative ICC patients.Patients who underwent curative - intent resection of ICC between 2011 and 2019 were identified from a large multi - institutional database. The impact of TBS, CEA, and the CTC grade on overall survival (OS) and recurrence - free survival (RFS) was evaluated in both the derivation and validation cohorts. The receiver operating characteristic curve was utilized for assessing the predictive accuracy of the model. Subgroup analyses were performed across 8th TNM stage system stratified by CTC grade to assess the discriminatory capacity within the same TNM stage.A total of 812 patients were included in the derivation cohort and 266 patients in the validation cohort. Survival varied based on CEA (low: 36.7% vs. high: 9.0%) and TBS (low: 40.3% vs. high: 17.6%) in relation to 5 - year survival (both p < 0.001). As expected, patients with low CTC grade (i.e., low TBS/low CEA) were associated with the best OS as well as RFS, while high CTC grade (i.e., high TBS/high CEA) correlated to the worst outcomes. The model exhibited well performance in both the derivation cohort (area under the curve of 0.694) and the validation cohort (0.664). The predictive efficacy of the CTC grade system remains consistently stable across TNM stages I and III/IV.The CTC grade, a composite parameter derived from the combination of TBS and CEA levels, served as an easy - to - use tool and performed well in stratifying patients with ICC relative to OS and RFS.© 2024. The Author(s).

基金：
National Key Research and DevelopmentProgram of China (2022YFC2407304); Major Research Projects for Youngand Middle-aged Researchers of Fujian Provincial Health Care Commission(2021ZQNZD013); and the Health Science and Technology InnovationPlatform Program of Fuzhou (2021-S-wp1).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者单位： [1]Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, 312 Xihong Road, Fuzhou, China [2]Department of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, 312 Xihong Road, Fuzhou, China [2]Department of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, China
推荐引用方式(GB/T 7714)：
Fu Jun,Zheng Lifang,Tang Shicuan,et al.Tumor burden score and carcinoembryonic antigen predict outcomes in patients with intrahepatic cholangiocarcinoma following liver resection: a multi&#x2011;institutional analysis[J].BMC CANCER.2024,24(1):358.doi:10.1186/s12885-024-12091-2.
APA：
Fu Jun,Zheng Lifang,Tang Shicuan,Lin Kongying,Zheng Shuguo...&Zeng Yongyi.(2024).Tumor burden score and carcinoembryonic antigen predict outcomes in patients with intrahepatic cholangiocarcinoma following liver resection: a multi&#x2011;institutional analysis.BMC CANCER,24,(1)
MLA：
Fu Jun,et al."Tumor burden score and carcinoembryonic antigen predict outcomes in patients with intrahepatic cholangiocarcinoma following liver resection: a multi&#x2011;institutional analysis".BMC CANCER 24..1(2024):358

相关文献

[1]Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort [2]Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer [3]Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer [4]Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer [5]A pair of primary colorectal cancer-derived and corresponding synchronous liver metastasis-derived organoid cell lines [6]Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer [7]Remarkably reduced expression of FoxO3a in metaplastic colorectum, primary colorectal cancer and liver metastasis [8]Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer [9]Expert consensus on the scheme of pathological diagnosis of primary liver cancer [10]Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

资源点击量：589 今日访问量：0 总访问量：441 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）